Sugi Predict

Sugi Predict / Compounds / SCHEMBL145353

SCHEMBL145353

SCHEMBL145353

Cc1cc(Br)cc(C)c1C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ HPGD P15428 4/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ APOBEC3G Q9HC16 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HAVCR2 Q8TDQ0 1/20 0.43
▸ RECQL P46063 4/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ UPP1 Q16831 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ LMNA P02545 3/20 0.39
▸ GAA P10253 4/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13868306 0.84 TRPV4 (0.43) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL11788967 0.84 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL31287347 0.84 UPP1 (0.43) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL31113834 0.84 TRPV4 (0.43) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL1629437 0.84 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL2024385 0.81 RECQL (0.43) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL18786799 0.80 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL31436552 0.80 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL8851985 0.78 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL1344362 0.78 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 — — EP disclosed
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2025-07-24 — — US disclosed
US-12195449-B2 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof BEIGENE, LTD. (KY) 2025-01-14 — — US disclosed
US-20240382482-A1 PLASMA KALLIKREIN INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2024-11-21 — — US disclosed
WO-2024216203-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES ACELOT, INC. (US) 2024-10-17 — — WO disclosed
US-20240317714-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2024-09-26 — — US disclosed
CN-117624131-A 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-03-01 — — CN disclosed
CN-117624130-A 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-03-01 — — CN disclosed
EP-4308228-A1 PLASMA KALLIKREIN INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2024-01-24 — — EP disclosed
CN-117396474-A Plasma kallikrein inhibitors 武田药品工业株式会社 2024-01-12 — — CN disclosed
US-20040038962-A1 Fused azepine derivatives and their use as antidiuretic agents VANTIA LIMITED (GB) 2004-02-26 — — US disclosed
EP-1294698-A1 FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS FERRING B.V. (NL) 2003-03-26 — — EP disclosed
WO-2003016316-A1 DIAZACYCLOALKANES AS OXYTOCIN AGONISTS FERRING B.V. (NL) 2003-02-27 — — WO disclosed
WO-2003016316-A1 DIAZACYCLOALKANES AS OXYTOCIN AGONISTS FERRING B.V. (NL) 2003-02-27 — — WO disclosed
WO-2003000692-A2 OXYTOCIN AGONISTS FERRING BV (NL) 2003-01-03 — — WO disclosed
WO-2002000626-A1 FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS FERRING B.V. (NL) 2002-01-03 — — WO disclosed
EP-0310904-A1 Treated substrates for chromatographic use KSV-Chemicals Oy (FI) 1989-04-12 — — EP disclosed
US-4756971-A Silicon compound or polysiloxane for treating hydrophilic surface such as glass KSV-CHEMICALS OY (FI) 1988-07-12 — — US disclosed
EP-0207977-A1 SURFACE TREATMENT AGENTS AND POLYMERS KSV-Chemicals Oy (FI) 1987-01-14 — — EP disclosed
WO-1986004063-A1 SURFACE TREATMENT AGENTS AND POLYMERS KSV-CHEMICALS OY (FI) 1986-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317714-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 KDM4E 1979/4885ALDH1A1 3197/4885HPGD 445/4885
US-20240382482-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 KDM4E 838/4885ALDH1A1 3175/4885HPGD 560/4885
US-20040038962-A1 Fused azepine derivatives and their use as antidiuretic agents AVPR2, AVPR1A, AVPR1B KDM4E 2827/4885ALDH1A1 1165/4885HPGD 414/4885
US-12195449-B2 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof HIPK1, HIPK3, HIPK2 KDM4E 1979/4885ALDH1A1 3197/4885HPGD 445/4885
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 KDM4E 1865/4885ALDH1A1 3156/4885HPGD 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.